Boundless Bio, a Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Boundless Bio is focused on developing therapies for oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1, which manages ecDNA replication and transcription in cancer cells. BBI-355 is currently being studied in a first-in-human, Phase 1/2 trial in patients with oncogene amplified cancers, with preliminary data expected in the 2H24.
The San Diego, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol BOLD. Goldman Sachs, Leerink Partners, Piper Sandler, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
